Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts.

van der Helm, L H; Veeger, N J G M; Kooy, M van Marwijk; Beeker, A; de Weerdt, O; de Groot, M; Alhan, C; Hoogendoorn, M; Laterveer, L; van de Loosdrecht, A A; Koedam, J; Vellenga, E; Huls, G

van der Helm, L H; Veeger, N J G M; Kooy, M van Marwijk; Beeker, A; de Weerdt, O; de Groot, M; Alhan, C; Hoogendoorn, M; Laterveer, L; van de Loosdrecht, A A; Koedam, J; Vellenga, E; Huls, G.

Affiliation

van der Helm LH; Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands.

Leuk Res ; 37(8): 877-82, 2013 Aug.

Article in En | MEDLINE | ID: mdl-23628552

Subject(s)

Azacitidine/therapeutic use; Bone Marrow Cells/drug effects; Bone Marrow/drug effects; Leukemia, Myeloid/drug therapy; Acute Disease; Aged; Aged, 80 and over; Azacitidine/administration & dosage; Bone Marrow/pathology; Bone Marrow Cells/pathology; Cell Count; Compassionate Use Trials; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid/blood; Leukemia, Myeloid/genetics; Male; Middle Aged; Outcome Assessment, Health Care; Remission Induction; Retrospective Studies

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Azacitidine / Bone Marrow / Bone Marrow Cells / Leukemia, Myeloid Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Leuk Res Year: 2013 Type: Article Affiliation country: Netherlands

Fulltext

XML

PubMed Links

Search on Google